Perspective Ev To Sales from 2010 to 2025
| CATX Stock | 2.52 0.03 1.20% |
EV To Sales | First Reported 2010-12-31 | Previous Quarter 63.33 | Current Value 48.42 | Quarterly Volatility 92.53814831 |
Check Perspective Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Perspective Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Total Revenue of 1.6 M or Gross Profit of 1.3 M, as well as many indicators such as Price To Sales Ratio of 54.85, Dividend Yield of 0.0 or PTB Ratio of 1.22. Perspective financial statements analysis is a perfect complement when working with Perspective Therapeutics Valuation or Volatility modules.
Perspective | Ev To Sales |
Latest Perspective Therapeutics' Ev To Sales Growth Pattern
Below is the plot of the Ev To Sales of Perspective Therapeutics over the last few years. It is the Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue. Perspective Therapeutics' EV To Sales historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Perspective Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Ev To Sales | 10 Years Trend |
|
Ev To Sales |
| Timeline |
Perspective Ev To Sales Regression Statistics
| Arithmetic Mean | 65.93 | |
| Coefficient Of Variation | 140.37 | |
| Mean Deviation | 51.14 | |
| Median | 56.48 | |
| Standard Deviation | 92.54 | |
| Sample Variance | 8,563 | |
| Range | 470 | |
| R-Value | (0.01) | |
| Mean Square Error | 9,175 | |
| R-Squared | 0.00005 | |
| Significance | 0.98 | |
| Slope | (0.14) | |
| Total Sum of Squares | 128,450 |
Perspective Ev To Sales History
About Perspective Therapeutics Financial Statements
Perspective Therapeutics investors use historical fundamental indicators, such as Perspective Therapeutics' Ev To Sales, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Perspective Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| EV To Sales | 63.33 | 48.42 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Perspective Stock Analysis
When running Perspective Therapeutics' price analysis, check to measure Perspective Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Perspective Therapeutics is operating at the current time. Most of Perspective Therapeutics' value examination focuses on studying past and present price action to predict the probability of Perspective Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Perspective Therapeutics' price. Additionally, you may evaluate how the addition of Perspective Therapeutics to your portfolios can decrease your overall portfolio volatility.